Table 2.
Characteristics of a subgroup of 284 subjects included in the logistic regression analysis.
| Factor | n = 175 (62%) | n = 32 (11%) | n = 77 (27%) | 3p Value |
|---|---|---|---|---|
| Vaccine schedule | ChAd/ChAd; | BNT/BNT | ChAd/BNT | <0.0001 |
| Sex (Male) | 81 (46%) | 11 (34%) | 37 (48%) | 0.965 |
| 1 Age | 55 (48–61) | 52 (43–60) | 52 (46–57) | 0.167 |
| 1 BMI | 23.84 (21.8–27.08) | 24.15 (21.65–27.15) | 23.84 (21.99–26.12) | 0.631 |
| Smoking | 18 (10%) | 1 (3%) | 15 (19%) | 0.148 |
| Diabetes | 3 (2%) | 5 (16%) | 1 (1%) | 0.411 |
| Cardiovascular diseases | 7 (4%) | 3 (9%) | 2 (3%) | 0.127 |
| Respiratory tract diseases | 2 (1%) | 3 (9%) | 0 (0%) | 0.747 |
| COVID-19 diagnosis | 4 (2%) | 0 (0%) | 4 (5%) | 0.264 |
| 2 Vaccine side effects | 66 (38%) | 12 (38%) | 36 (47%) | 0.697 |
1 Median (IQR). 2 i.e., local pain, headache, malaise, fatigue, fever, feverish, muscle ache, joint pain, nausea as self-reported in the 48 h after vaccination. 3 Logistic regression analysis, fixing a cut-off of IgG response at 2080 BAU/mL (upper limit of assay).